In the most recent revision of the WHO classification, one provisional and two definitive entities are defined by specific sequence variants (RUNX1, NPM1 and bi-allelic CEBPA, respectively) based on the accumulating evidence that supports the role of gene mutations in AML biology [11]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.